The World Health Organization (WHO) prepares for the next pandemic; new restrictions on reproductive health services in the South; Thermo Fisher Scientific receives FDA approval for a first-of-its-kind preeclampsia test.
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus called on countries to implement necessary reforms and honor financial commitments to prepare for future pandemics during the annual World Health Assembly in Geneva, according to Reuters. Ghebreyesus emphasized the need for negotiating preventive measures to tackle the next global health crisis and warned that delaying action would only invite future pandemics. Additionally, the assembly discussed negotiations for a pandemic treaty and the approval of the WHO’s 2024-2025 budget.
As abortion options in the South grow more limited as lawmakers push for stricter restrictions, many Southerners may not have the ability to travel long distances to access abortion care in other states, according to NBC News. North Carolina is set to implement a ban on abortions after 12 weeks of pregnancy, while South Carolina's House of Representatives has approved a 6-week abortion ban. Furthermore, experts fear that the departure of many physicians from states with abortion bans will further limit access to abortions and maternal health care in the South.
Thermo Fisher Scientific has received FDA clearance for a first-of-its-kind test in the United States designed to detect women at risk of severe preeclampsia, according to Reuters. Preeclampsia, a condition characterized by high blood pressure during pregnancy and the postpartum period, is a leading cause of maternal mortality worldwide. The biomarker test is expected to significantly improve the prognosis and treatment of thousands of at-risk women in the United States each year.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More